文献速递泌尿男性生殖肿瘤

FLAME III期随机试验:前列腺内可见病灶局部加量放疗改善生化无病生存

Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial.
PubMed 文献 · J Clin Oncol · 2021-01-20

FLAME III期多中心随机试验纳入571例中高危局限期前列腺癌患者,比较标准放疗(全前列腺77 Gy)与针对多参数MRI可见前列腺内病灶的同步整合局部加量(至95 Gy)的疗效。

要点

  • 中高危局限期前列腺癌局部加量至95 Gy较标准77 Gy显著改善5年bDFS。
  • 局部加量组5年bDFS为92%,标准组为85%,HR 0.45(95%CI 0.28-0.71)。
  • 两组晚期≥2级泌尿生殖毒性和胃肠道毒性及生活质量差异无统计学意义。

核心结论

  • 对局限期中高危前列腺癌,在多参数MRI可见前列腺内病灶处同步整合局部加量至95 Gy,可改善生化无病生存,且不增加毒性和不影响生活质量。

研究设计与样本

  • III期多中心随机对照FLAME试验,2009至2015年纳入571例中高危局限期前列腺癌患者。

主要发现

  • 5年生化无病生存率局部加量组为92%,标准组为85%。
  • 晚期≥2级泌尿生殖毒性标准组23%、局部加量组28%;晚期≥2级胃肠道毒性标准组12%、局部加量组13%,差异小且无统计学意义。

关键数值与推荐

  • 标准组:全前列腺77 Gy,分次2.2 Gy。
  • 局部加量组:对多参数MRI可见前列腺内病灶同步整合加量至95 Gy,分次最高2.7 Gy。
  • 危及器官约束优先于局部加量剂量。

临床怎么用

  • 对中高危局限期前列腺癌,可在满足危及器官剂量约束前提下,对多参数MRI可见前列腺内病灶实施局部加量以改善生化控制。
  • 局部加量未显著增加晚期泌尿生殖和胃肠道毒性,可作为安全策略考虑。

局限性

  • 中位随访72个月,总生存和前列腺癌特异性生存事件可能不足。
  • 局部加量需依赖多参数MRI定位可见病灶。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study investigates whether focal boosting of the macroscopic visible tumor with external beam radiotherapy increases biochemical disease-free survival (bDFS) in patients with localized prostate cancer. PATIENTS AND METHODS: In the phase III, multicenter, randomized controlled Focal Lesion Ablative Microboost in Prostate Cancer trial, 571 patients with intermediate- and high-risk prostate cancer were enrolled between 2009 and 2015. Patients assigned to standard treatment received 77 Gy (fractions of 2.2 Gy) to the entire prostate. The focal boost arm received an additional simultaneous integrated focal boost up to 95 Gy (fractions up to 2.7 Gy) to the intraprostatic lesion visible on multiparametric magnetic resonance imaging. Organ at risk constraints were prioritized over the focal boost dose. The primary end point was 5-year bDFS. Secondary end points were disease-free survival (DFS), distant metastases-free survival, prostate cancer-specific survival, overall survival, toxicity, and health-related quality of life. RESULTS: Median follow-up was 72 months. Biochemical DFS was significantly higher in the focal boost compared with the standard arm (hazard ratio 0.45, 95% CI, 0.28 to 0.71, P < .001). At 5-year follow-up bDFS was 92% and 85%, respectively. We did not observe differences in prostate cancer-specific survival (P = .49) and overall survival (P = .50). The cumulative incidence of late genitourinary and GI toxicity grade ≥ 2 was 23% and 12% in the standard arm versus 28% and 13% in the focal boost arm, respectively. Both for late toxicity as health-related quality of life, differences were small and not statistically significant. CONCLUSION: The addition of a focal boost to the intraprostatic lesion improved bDFS for patients with localized intermediate- and high-risk prostate cancer without impacting toxicity and quality of life. The Focal Lesion Ablative Microboost in Prostate Cancer study shows that a high focal boost strategy to improve tumor control while respecting organ at risk dose constraints is effective and safe.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Kerkmeijer LGW, Groen VH, Pos FJ, et al. Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial. J Clin Oncol. 2021. PMID: 33471548. doi:10.1200/JCO.20.02873

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。